Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUOFUCON Silver Alginate Dressing is a **sterile, single-use wound therapy dressing** combining *calcium alginate fibers derived from seaweed* with *silver particles*[1][2][5]. The calcium alginate absorbs wound exudate and forms a gel-like covering at the wound site, *promoting moist healing, absorbing exudate, minimizing pain during changes, and preventing the dressing from adhering*[1][2][5]. Silver particles are gradually released, providing **broad-spectrum antimicrobial action** against Gram-positive and Gram-negative bacteria (including MRSA and VRE) for up to 7 days[2][3][5][9]. This mechanism protects both the wound and the dressing from infection, supporting healing of *moderate to heavily exuding partial- and full-thickness wounds* (pressure ulcers, diabetic foot ulcers, venous ulcers, post-surgical wounds, graft/donor sites, traumatic wounds), and can also be used over-the-counter for minor abrasions, cuts, lacerations, and burns[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on luofucon silver alginate.